Literature DB >> 35124956

Endoscopic balloon dilations for strictures of rectum, ileocecal valve and duodenum in a patient with X-linked inhibitor of apoptosis deficiency: a case report.

Shinsuke Otagiri1, Takehiko Katsurada2, Kensuke Sakurai1, Junichi Sugita3, Naoya Sakamoto1.   

Abstract

X-linked inhibitor of apoptosis (XIAP) deficiency is a rare primary immunodeficiency and gastrointestinal (GI) lesions in XIAP deficiency are similar to Crohn's disease. For patients with Crohn's disease, endoscopic balloon dilation (EBD) is known to be a standard procedure for intestinal strictures including upper GI tract. However, there are no articles which mention the efficacy of EBDs for the strictures in upper GI tract in patients with XIAP deficiency. Herein, we describe an 18-year-old male with XIAP deficiency in whom EBDs for the rectum, ileocecal valve (ICV), and duodenum were performed. Before hematopoietic stem cell transplantation (HSCT), GI endoscopy revealed strictures of the rectum, ICV and duodenum with active ulcers. Although these ulcers healed after HSCT, the strictures progressed. Therefore, we performed EBDs for the strictures of the rectum, ICV, and duodenum. In contrast studies, we did not find any other strictures in the small intestine. Throughout the patient's clinical course, no complications of EBD occurred. He started eating after EBDs, but abdominal symptoms did not relapse without any dietary restrictions. Our case suggests that EBD could be an effective and safe procedure for intestinal strictures including upper GI tract after HSCT in patients with XIAP deficiency.

Entities:  

Keywords:  Case reports; Endoscopy; Gastrointestinal diseases; Hematopoietic stem cell transplantation; X-linked inhibitor of apoptosis protein

Year:  2022        PMID: 35124956      PMCID: PMC9081990          DOI: 10.5217/ir.2021.00029

Source DB:  PubMed          Journal:  Intest Res        ISSN: 1598-9100


INTRODUCTION

X-linked inhibitor of apoptosis (XIAP) deficiency is a rare primary immunodeficiency, and the incidence of mutations in XIAP is estimated to be 1–2 cases per million live births [1]. The main clinical manifestations are hemophagocytic lymphohistiocytosis, splenomegaly, and gastrointestinal (GI) lesions. The clinical and histological features of GI lesions in patients with XIAP deficiency are similar to those in patients with Crohn’s disease (CD) [2]. It was demonstrated that 4% of male patients with pediatric-onset CD had private variants in XIAP [3]. GI lesions in XIAP deficiency are generally severe and drug-resistant, and the only curative treatment is hematopoietic stem cell transplantation (HSCT) [4]. It is possible that patients with XIAP deficiency may develop intestinal strictures like those with CD [5]. In patients with CD, endoscopic balloon dilation (EBD) is known to be a standard procedure for intestinal strictures [6]. We reported another case of a patient with XIAP deficiency who underwent EBDs after HSCT for a stricture of the ileocecal valve (ICV) [7]. However, there are no articles which mention the safety and efficacy of EBDs for the intestinal strictures including upper GI tract in patients with XIAP deficiency. Herein, we describe a case of XIAP deficiency in whom EBDs for multiple strictures of rectum, ICV and duodenum were performed after HSCT. The study’s protocol was waived by the Institutional Review Board of Hokkaido University Hospital. Written informed consent was obtained.

CASE REPORT

An 18-year-old boy with XIAP deficiency was referred to our hospital for HSCT. He was diagnosed as having CD when he was 11 years of age in another hospital. He had been treated with various treatments such as steroids, azathioprine, infliximab, adalimumab, or ustekinumab. Nevertheless, clinical remission had never been achieved. Moreover, he repeatedly developed hemophagocytic lymphohistiocytosis. Therefore, genetic analysis was performed, and it revealed XIAP deficiency. Before HSCT, colonoscopy revealed multiple active ulcers in the large intestine (Fig. 1A and B), a mild stricture of the rectum (Fig. 2A) and a severe stricture of the ICV (Fig. 3A) with active ulcers. Moreover, esophagogastroduodenoscopy revealed a mild stricture in the duodenum with an active ulcer (Fig. 4A). Due to these strictures and multiple ulcers, he could only consume a concentrated liquid diet. After HSCT, the strictures of the rectum (Fig. 2B) and duodenum (Fig. 4B) progressed, and the nasal endoscope could not be advanced through these strictures. Since the active ulcers were healing, we decided to perform EBDs. We first dilated the stricture of the rectum using a through-the-scope balloon up to 12 mm (Fig. 2C and D), and the scope could be advanced. The multiple ulcers in the large intestine were healing (Fig. 1C and D), and the stricture of the ICV remained severe (Fig. 3B). Next, we dilated the stricture of the ICV up to 10 mm (Fig. 3C and D), and the scope could be advanced. Finally, we performed EBD for the stricture of the duodenum up to 10 mm (Fig. 4C and D). Throughout the patient’s clinical course, no EBD complications occurred. In contrast studies, we did not find any other strictures in the small intestine (Fig. 5). He started eating after the EBDs, but abdominal symptoms did not relapse without any dietary restrictions. We have been following him for 4 months and the GI patency is maintained without any symptoms.
Fig. 1.

Endoscopic images of the large intestine. Before hematopoietic stem cell transplantation (HSCT), multiple longitudinal ulcers in the transverse colon (A) and descending colon (B) were observed. After HSCT, these ulcers were healing in the transverse colon (C) and descending colon (D).

Fig. 2.

Endoscopic and fluoroscopic images of the rectum. Before hematopoietic stem cell transplantation (HSCT), the rectum was mildly stenosed with active ulcers (A). After HSCT, active ulcers were healing; however, the stricture of the rectum progressed (B). We performed endoscopic balloon dilations for the rectum up to 12 mm (C, D).

Fig. 3.

Endoscopic and fluoroscopic images of the ileocecal valve (ICV). Before hematopoietic stem cell transplantation (HSCT), the ICV was severely stenosed with an active ulcer (A). After HSCT, the active ulcer was healing, and the stricture of the ICV remained severe (B). We performed endoscopic balloon dilations for the ICV up to 10 mm (C, D).

Fig. 4.

Endoscopic and fluoroscopic images of the duodenum. Before hematopoietic stem cell transplantation (HSCT), the duodenum bulb was mildly stenosed with an active ulcer (A). After HSCT, the active ulcer was healing; however, the stricture of the duodenum progressed (B). We performed endoscopic balloon dilations for the rectum up to 10 mm (C, D).

Fig. 5.

Fluoroscopic images of the small intestine (A, B). In contrast studies, no other stricture in the small intestine was observed.

DISCUSSION

XIAP deficiency is mostly a pediatric, drug-resistant disease, and its symptoms are generally severe. The only curative treatment for XIAP deficiency is HSCT, and a previous study revealed the efficacy of HSCT for GI lesions [8]. In the present case, the patient had been treated with various treatments for CD, but no drugs were remarkably effective for his GI lesions. However, mucosal healing was achieved after HSCT, as previously reported. Little has been reported about HSCT being associated with a risk of proceeding GI strictures in patients with XIAP deficiency. In cases of CD, it was reported that rapid mucosal healing by anti-tumor necrosis factor-α antibodies may result in excess scar tissue formation and strictures [9]. GI lesions in XIAP deficiency are similar to those in CD [2]. Thus, in the present case, it was possible for the fibrotic strictures to progress during the process of subsiding inflammation, as in CD. There is no standard procedure for treating strictures in XIAP deficiency; therefore, we referred to the strategy used for treating strictures in patients with CD because of the similarity between XIAP deficiency and CD. Previous studies reported that performing EBD for intestinal strictures in patients with CD is safe and effective to avoid surgery [6]. There are some criteria regarding EBDs for CD: (1) a short stricture (< 4 cm) with minimal inflammation, (2) lack of malignancy or high-grade dysplasia, (3) lack of a fistula orifice close to the stricture or an abscess in the stricture area, and (4) straight strictures in line with the bowel lumen [10]. Previous studies reported that main complications of EBD for CD are acute bleeding and perforations, and a larger balloon size may be associated with a higher complication rate [11]. In the present case, the strictures met the criteria of EBD for CD; therefore, we chose this procedure as treatment. Our patient’s strictures were very severe, so we dilated the strictures with a small balloon size (10–12 mm) to minimize the risk of complications. Consequently, no complications of EBD occurred, and clinical remission was achieved without any dietary restrictions or surgery. Little is known about the effects of EBD for strictures of upper GI tract in patients with CD; however, in a meta-analysis, Bettenworth et al. [12] suggested that EBD for CD-associated strictures of the upper GI tract to be a valuable alternative to surgery, with a high rate of short-term technical and clinical success, moderate long-term efficacy, and an acceptable rate of complications. Like CD patients, our case suggests that EBD could be an effective and safe procedure for strictures of upper GI tract in patients with XIAP deficiency. In conclusion, EBD could be an effective and safe procedure for intestinal strictures including upper GI tract after HSCT in patients with XIAP deficiency. XIAP deficiency patients with intestinal strictures after HSCT could avoid surgery, if EBD is properly performed.
  9 in total

1.  IBD LIVE Case Series--Case 3: Very Early-Onset Inflammatory Bowel Disease: When Genetic Testing Proves Beneficial.

Authors:  Whitney M Sunseri; Subra Kugathasan; David J Keljo; Julia B Greer; Sarangarajan Ranganathan; Raymond K Cross; Corey A Siegel; Miguel D Regueiro
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

Review 2.  XIAP deficiency syndrome in humans.

Authors:  Sylvain Latour; Claire Aguilar
Journal:  Semin Cell Dev Biol       Date:  2015-02-07       Impact factor: 7.727

3.  Gastrointestinal: Endoscopic balloon dilations for an intestinal stricture in a patient with X-linked inhibitor of apoptosis deficiency.

Authors:  S Otagiri; R Sugiura; T Katsurada; K Yamanashi; K Nagashima; J Sugita; S Ohnishi; N Sakamoto
Journal:  J Gastroenterol Hepatol       Date:  2019-06-07       Impact factor: 4.029

4.  Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease.

Authors:  A Gustavsson; A Magnuson; B Blomberg; M Andersson; J Halfvarson; C Tysk
Journal:  Aliment Pharmacol Ther       Date:  2012-05-22       Impact factor: 8.171

5.  Successful treatment of idiopathic colitis related to XIAP deficiency with allo-HSCT using reduced-intensity conditioning.

Authors:  Yusuke Tsuma; Toshihiko Imamura; Eisuke Ichise; Kenichi Sakamoto; Kazutaka Ouchi; Shinya Osone; Hiroyuki Ishida; Taizo Wada; Hajime Hosoi
Journal:  Pediatr Transplant       Date:  2014-11-21

6.  Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn's disease strictures.

Authors:  Ashish Atreja; Ashish Aggarwal; Saurabh Dwivedi; Florian Rieder; Rocio Lopez; Bret A Lashner; Aaron Brzezinski; John J Vargo; Bo Shen
Journal:  J Crohns Colitis       Date:  2013-11-01       Impact factor: 9.071

Review 7.  Intestinal stricture in Crohn's disease.

Authors:  Chen-Wang Chang; Jau-Min Wong; Chien-Chih Tung; I-Lun Shih; Horng-Yuan Wang; Shu-Chen Wei
Journal:  Intest Res       Date:  2015-01-29

Review 8.  Endoscopic Balloon Dilation for Crohn's Disease-Associated Strictures.

Authors:  Thomas Klag; Jan Wehkamp; Martin Goetz
Journal:  Clin Endosc       Date:  2017-09-29

9.  Efficacy of Endoscopic Dilation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data.

Authors:  Dominik Bettenworth; Marcus M Mücke; Rocio Lopez; Amandeep Singh; Weiming Zhu; Feilong Guo; Toshiyuki Matsui; Theodore W James; Hans Herfarth; Martin Goetz; Ren Mao; Satya Kurada; Jochen Hampe; Katja Matthes; John Gásdal Karstensen; Piero V Valli; Marjolijn Duijvestein; Geert D'Haens; Vipul Jairath; Tian Bai Qiu; Nik Sheng Ding; Gerhard Rogler; Florian Rieder
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-29       Impact factor: 11.382

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.